Literature DB >> 24955185

CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics.

Ali Babacan1, Cem Kizilaslan2, Ismet Gun1, Murat Muhcu1, Ercument Mungen1, Vedat Atay1.   

Abstract

The aim of this study was to investigate the factors associated with serum levels of several tumor markers in a group of patients operated for uterine myoma. One hundred thirty-seven female patients operated for uterine myoma were included. Serum samples were examined for CA 125, CA 19-9, CA 15-3, carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) levels as part of routine workup. Pathological and morphological characteristics of the patients were retrieved from medical records. The mean age was 46.7 ± 8.8 years (range, 22-85 y). Abnormally high levels of CA 125, CA 19-9, CA 15-3, CEA, and AFP were found in 19.7%, 6.6%, 5.1%, 3.7%, and 1.5% of the patients, respectively. Patients with additional adenomyosis and patients with at least one large myoma (≥ 5 cm diameter) had significantly higher levels of CA 125. Multivariate analysis identified coexistence of adenomyosis (OR 7.7 [95% CI, 2.6-23.0], p < 0.001) and presence of at least one large myoma (OR 5.6 [1.4-22.8], p = 0.016) as independent predictors of abnormally high CA 125 levels. CA 125 levels are affected by the tumor size and coexistence of adenomyosis in uterine leiomyomas. Indirect mechanisms caused by large myoma size such as peritoneal irritation may be responsible for CA 125 elevations.

Entities:  

Keywords:  CA 125; CA 15-3; CA 19-9; Uterine leiomyoma; alpha fetoprotein (AFP); carcinoembryonic antigen (CEA); tumor marker; uterine fibroma

Year:  2014        PMID: 24955185      PMCID: PMC4057864     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  22 in total

1.  Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  A Vodolazkaia; Y El-Aalamat; D Popovic; A Mihalyi; X Bossuyt; C M Kyama; A Fassbender; A Bokor; D Schols; D Huskens; C Meuleman; K Peeraer; C Tomassetti; O Gevaert; E Waelkens; A Kasran; B De Moor; T M D'Hooghe
Journal:  Hum Reprod       Date:  2012-06-26       Impact factor: 6.918

2.  Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma.

Authors:  C M Juang; M S Yen; H C Horng; N F Twu; H C Yu; W L Hsu
Journal:  Eur J Gynaecol Oncol       Date:  2006       Impact factor: 0.196

Review 3.  Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

Authors:  Lidia Rosi Medeiros; Daniela Dornelles Rosa; Maria Inês da Rosa; Mary Clarisse Bozzetti
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2008-11-07       Impact factor: 2.435

4.  Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.

Authors:  Z M van der Spuy; M Wood; G Fieggen; M S Hendricks
Journal:  S Afr Med J       Date:  1993-07

5.  The effect of hysterectomy on serum CA 125 levels in patients with adenomyosis and uterine fibroids.

Authors:  H Halila; A M Suikkari; M Seppälä
Journal:  Hum Reprod       Date:  1987-04       Impact factor: 6.918

6.  Peripheral CA 125 levels in patients with uterine fibroids.

Authors:  P Bischof; M A Galfetti; J Seydoux; J U von Hospenthal; A Campana
Journal:  Hum Reprod       Date:  1992-01       Impact factor: 6.918

7.  Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas.

Authors:  M Y Dawood; F S Khan-Dawood
Journal:  Fertil Steril       Date:  1994-04       Impact factor: 7.329

8.  [Differential diagnosis between leiomyomata uteri and adenomyosis using CA 125 as a new tumor marker of ovarian carcinoma].

Authors:  K Takahashi; S Kijima; K Yoshino; T Shibukawa; M Moriyama; O Iwanari; K Sawada; I Matsunaga; F Murao; M Kitao
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1985-04

9.  [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].

Authors:  E Kimura; M Murae; R Koga; Y Odawara; Y Nakabayashi; K Yokoyama; H Nakata; T Totake; K Ochiai; M Yasuda
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1984-11

10.  Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.

Authors:  Kuo-Chien Tsao; Ji-Hong Hong; Tsu-Lan Wu; Pi-Yueh Chang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

View more
  5 in total

1.  Abdominopelvic leiomyoma with large ascites: A case report and review of the literature.

Authors:  Yi-Wei Wang; Qiong Fan; Zhao-Xia Qian; Jin-Jin Wang; Yu-Hong Li; Yu-Dong Wang
Journal:  World J Clin Cases       Date:  2021-02-26       Impact factor: 1.337

2.  Retroperitoneal Hydropic Leiomyoma Mimicking an Ovarian Cyst.

Authors:  Pei-Hsuan Lai; Dah-Ching Ding
Journal:  Case Rep Obstet Gynecol       Date:  2022-08-04

3.  Uterine fibroids with positive 18F-FDG PET/CT image and significantly increased CA19-9: A case report.

Authors:  Yan Ma; Xiaonan Shao
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

4.  Cerebral infarction associated with benign mucin-producing adenomyosis: report of two cases.

Authors:  Koki Okazaki; Fumiaki Oka; Hideyuki Ishihara; Michiyasu Suzuki
Journal:  BMC Neurol       Date:  2018-10-04       Impact factor: 2.474

5.  Vaginal leiomyoma: medical imaging and diagnosis in a resource low tertiary hospital: case report.

Authors:  Thomas Obinchemti Egbe; Fidelia Mbi Kobenge; Junette Arlette Mbengono Metogo; Emmanuella Manka'a Wankie; Paul N Tolefac; Eugene Belley-Priso
Journal:  BMC Womens Health       Date:  2020-01-21       Impact factor: 2.809

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.